The ADMdx difference delivers remarkable clarity

At AMDdx, we are committed to continually growing and refining our diverse and extensive database so we can continue to develop proprietary, cutting-edge technologies that enable earlier, more accurate disease diagnosis, outcome prediction, and detection of treatment effect.

Our unparalleled forms of brain measurement not only extract actionable insights from MRI and PET images and other data to advance clinical care and drug development—they also allow us opportunities for education across the ever-complicated brain disease landscape.

ADMdx addresses key challenges in clinical trials and in the clinical setting with focus areas on Alzheimer’s disease, Parkinson’s disease, and most neurodegenerative and neuropsychiatric disorders. We combine our technology advances with extensive quality control, 21 CFR Part 11 compliance, and commitment to meeting customer needs.

At ADMdx, we address key challenges in the clinical setting with our clear report. CorInsights^®! MRI provides easy-to-understand insights for medical professionals, and easy-to-comprehend charts and graphs meant to be shared with patients and their loved ones. CorInsights MRI is just the beginning.

ADMdx takes a forward-thinking, collaborative approach to our quantitative brain imaging. Our extensive collaborations with top researchers and institutions are advancing the diagnostic and therapeutic research landscape at every turn.

At ADMdx, we believe advancing the diagnostic brain imaging industry through education and thought leadership are not lofty goals but key principles of our work. Our team has authored countless papers in academic publications, garnered ongoing positive press, penned various white papers, videos, webinars and articulated much more.